Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery

Huang, Meng-Yi; Pu, Yanchi; Yao, Peng; Fu, Qiuyi; Guo, Li; Wu, Yong; Zheng, Yongxiang

doi:10.1016/j.bmcl.2020.127151

Cited by 26 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeted properties of liposomes can be achieved by conjugation with ligands. Although the mono-targeting ligand can promote the binding and internalization of liposomes into the cancer cells, only a few liposomes with high targeting efficiency have been developed so far, because the traditional mono-branched ligand modified liposomes generally fail to deliver an adequate therapeutic payload [85]. Studies showed that functionalization with folic acid resulted in reduced drug uptake into noncancerous cells, higher cytotoxicity to cancer cells with FR overexpression, better tumour shrinkage efficiency, prolonged mice survival time, reduced mice weight loss and much lower toxicity compared to free drug or not targeted drug-loaded liposomes [67][68][69][70][71][72].…”

Section: Drug Delivery Application Single-drug Deliverymentioning

confidence: 99%

“…The recent studies on nanoparticles dual-targeted with biotin are presented in Table 6. Liposomes dual-targeted with biotin and glucose (Bio-Glu-Lip) and loaded with paclitaxel were evaluated for breast tumour-specific drug delivery, improvement of the efficacy and reduction of the chemotherapy side effects [85].…”

Section: Dual-targeting With Biotinmentioning

confidence: 99%

“…Bio-Glu-Lip had the highest cell uptake in 4T1 and MCF-7 cells when compared to the non-targeting liposome (Lip), Bio-Lip and Glu-Lip. In addition, significantly increased accumulation of the Bio-and Glu-targeted liposomes in the breast tumour sites was observed [85]. A new strategy was developed to simultaneously introduce a nuclear protein-highmotility group box (HMGB)-1 for nuclear transport and biotin for particular tumour cell targeting [170].…”

Section: Dual-targeting With Biotinmentioning

confidence: 99%

See 2 more Smart Citations

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

Section: Drug Delivery Application Single-drug Deliverymentioning

confidence: 99%

Section: Dual-targeting With Biotinmentioning

confidence: 99%

Section: Dual-targeting With Biotinmentioning

confidence: 99%

See 1 more Smart Citation

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The sodium-dependent multivitamin transporter (SMVT) is a key transporter for biotin overexpression on the surface of breast cancer cells (4T1 and McF-7), and GLUT1 is overexpressed in different types of tumor cells. Huang et al (65) synthesized biotin-glucose-branched ligandmodified paclitaxel double-targeted liposome (PTX-Bio-Glu-Lip) for precise targeting of breast cancer cells. The conventional paclitaxel liposome (PTX-Lip) and the single modified biotin-paclitaxel liposome (PTX-Bio-lip) and glucose-paclitaxel liposome (PTX-Glu-Lip) were used as reference.…”

Section: Dual-ligand Liposomesmentioning

confidence: 99%

Strategies for Liposome Drug Delivery Systems to Improve Tumor Treatment Efficacy

Gong

Wei

2021

AAPS PharmSciTech

View full text Add to dashboard Cite

In the advancement of tumor therapy, in addition to the search for new antitumor compounds, the development of nano-drug delivery systems has opened up new pathways for tumor treatment by addressing some of the limitations of traditional drugs. Liposomes have received much attention for their high biocompatibility, low toxicity, high inclusivity, and improved drug bioavailability. They are one of the most studied nanocarriers, changing the size and surface characteristics of liposomes to better fit the tumor environment by taking advantage of the unique pathophysiology of tumors. They can also be designed as tumor targeting drug delivery vehicles for the precise delivery of active drugs into tumor cells. This paper reviews the current development of liposome formulations, summarizes the characterization methods of liposomes, and proposes strategies to improve the effectiveness of tumor treatment. Finally, it provides an outlook on the challenges and future directions of the field.

show abstract

“…Nanocarrier-based drug delivery system can not only make up for the shortcomings of general drugs such as short circulation time, poor stability, low bioavailability and systemic toxic reaction, but also target the lesion and control the release rate of the drug to improve the therapeutic effect. 8 At present, researchers have developed a large number of organic or inorganic nanomaterials for drug delivery to treat various diseases, such as liposomes, [9][10][11][12] polymer micelles, [13][14][15][16] gold nanoparticles, [17][18][19] carbon nanotubes, [20][21][22] quantum dots, [23][24][25] metal oxides, 26,27 and mesoporous silica. 28,29 Compared with other nanomaterials, mesoporous silica has been widely used in the construction of nanoplatforms for drug delivery due to its flexible size, high specific surface area, controlled pore volume, high drug loading capacity, high biocompatibility, good hydrothermal stability, and surface chemical modification.…”

Section: Introductionmentioning

confidence: 99%

The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis

Sha¹,

Dai²,

Song³

et al. 2021

IJN

View full text Add to dashboard Cite

Atherosclerosis (AS) as the leading cause of cardiovascular and cerebrovascular events has been paid much attention all the time. With the continuous development of modern medical drug treatment, surgical treatment, interventional treatment and other methods, the mortality rate of AS has shown a downward trend, while the morbidity rate is still increasing. Oral lipid-lowering or anti-inflammatory drugs are generally used for early AS, but the relatively low accumulation efficiency in lesions and the unavoidable side effects required researchers to develop more effective drug delivery approaches for the therapy of AS. Mesoporous silica nanoparticles as nanocarrier for drug delivery have received extensive attentions due to their flexible size, high specific surface area, controlled pore volume, high drug loading capacity and excellent biocompatibility. Series of good reviews about the mesoporous silica nanoparticles loaded drugs for cancer therapy have been well documented. However, their roles as nanocarrier for drug delivery to treat AS have few reports. In this review, the applications and challenges of mesoporous silica nanomaterials in the field of the diagnosis and therapy of AS have been summarized. The classification, synthesis, formation mechanism, surface modification and functionalization of mesoporous silica nanomaterials which were closely related to the theranostic effect of AS have also been included. Last but not the least, the future prospects’ suggestions of mesoporous silica nanomaterial-based drug delivery system for AS are also provided.

show abstract

Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery

Cited by 26 publications

References 25 publications

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Strategies for Liposome Drug Delivery Systems to Improve Tumor Treatment Efficacy

The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis

Contact Info

Product

Resources

About